IMMX Earnings Date: Nov 6, 2026 (Estimated) — Immix Biopharma, Inc.
NASDAQ
Updated
When is IMMX's next earnings date?
Immix Biopharma, Inc. (IMMX) is expected to report Q3 2026 earnings on Friday, November 6, 2026 at 5:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.18.
How did IMMX do in its last earnings report?
In its most recent report on Aug 7, 2026 (Q2 2026), Immix Biopharma, Inc. posted EPS of -$0.18 versus the -$0.17 estimate, a miss of 5.9%. Revenue was $0. The stock's 1-day post-earnings move was +4.2%.
How much does IMMX stock move after earnings?
IMMX beat EPS estimates in 2 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 2.9% (up or down) in the day after earnings.
About Immix Biopharma, Inc.
Immix Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to creating a range of tissue-specific therapies. Operating in both the United States and Australia, their primary focus areas are oncology (cancer) and inflammatory diseases. Their product pipeline includes IMX-110, which is currently undergoing Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and various solid tumors. They are also developing IMX-111, a targeted biologic agent for colorectal cancers, and IMX-120, another tissue-specific biologic designed to address ulcerative colitis and severe Crohn's disease. In a strategic move, the company has forged a clinical collaboration and supply agreement with BeiGene Ltd. This partnership aims to conduct a Phase 1b combination clinical trial, evaluating IMX-110 in conjunction with BeiGene's anti-PD-1 drug, Tislelizumab, for solid tumor indications. Founded in 2012, Immix Biopharma maintains its headquarters in Los Angeles, California.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-07 | Q2 2026 | -0.17 | -0.18 | -5.88% | $0 | ❌ Miss | +4.22% | +12.86% | +36.32% |
| 2026-05-07 | Q1 2026 | -0.21 | -0.18 | +14.29% | $0 | ✅ Beat | +2.20% | +5.87% | -17.51% |
| 2026-03-25 | Q4 2025 | -0.16 | -0.28 | -75.00% | $0 | ❌ Miss | -2.13% | -3.25% | +10.55% |
| 2025-11-07 | Q3 2025 | -0.18 | -0.24 | -33.33% | $0 | ❌ Miss | +2.86% | +33.65% | +109.52% |
| 2025-08-08 | Q2 2025 | -0.16 | -0.22 | -37.50% | $0 | ❌ Miss | -2.93% | -5.02% | -4.60% |
| 2024-08-12 | Q2 2024 | -0.21 | -0.15 | +28.57% | $0 | ✅ Beat | +0.54% | +12.97% | +0.54% |
| 2024-03-29 | Q4 2023 | -0.23 | -0.24 | -4.35% | $0 | ❌ Miss | -4.89% | -6.51% | -30.94% |
| 2023-11-13 | Q3 2023 | -0.23 | -0.23 | +0.00% | $0 | ➖ Inline | +3.53% | +3.76% | -1.88% |
Showing last 8 quarters.